{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:16:22Z","timestamp":1783404982673,"version":"3.54.6"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"13","funder":[{"name":"Hospital-level disciplines-Support Group-Prostate Tumor Center","award":["YJXK-2021-18"],"award-info":[{"award-number":["YJXK-2021-18"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec><jats:title>Background::<\/jats:title><jats:p>BLCA is a common urothelial malignancy characterized by a high recurrence rate. Despite its prevalence, the molecular mechanisms underlying its development remain unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims::<\/jats:title><jats:p>This study aimed to explore new prognostic biomarkers and investigate the underlying mechanism of bladder cancer (BLCA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective::<\/jats:title><jats:p>The objective of this study is to identify key prognostic biomarkers for BLCA and to elucidate their roles in the disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods::<\/jats:title><jats:p>We first collected the overlapping DEGs from GSE42089 and TCGA-BLCA samples for the subsequent weighted gene co-expression network analysis (WGCNA) to find a key module. Then, key module genes were analyzed by the MCODE algorithm, prognostic risk model, expression and immunohistochemical staining to identify the prognostic hub gene. Finally, the hub gene was subjected to clinical feature analysis, as well as cellular function assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results::<\/jats:title><jats:p>In WGCNA on 1037 overlapping genes, the blue module was the key module. After a series of bioinformatics analyses, POLE2 was identified as a prognostic hub gene in BLCA from potential genes (TROAP, POLE2, ANLN, and E2F8). POLE2 level was increased in BLCA and related to different clinical features of BLCA patients. Cellular assays showed that si-POLE2 inhibited BLCA proliferation, and si-POLE2+ 740Y-P in BLCA cells up-regulated the PI3K and AKT protein levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion::<\/jats:title><jats:p>In conclusion, POLE2 was identified to be a promising prognostic biomarker as an oncogene in BLCA. It was also found that POLE2 exerts a promoting function by the PI3K\/AKT signaling pathway in BLCA.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0113862073273633231113060429","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T06:43:50Z","timestamp":1701326630000},"page":"1984-1998","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth via the PI3K\/AKT Signaling Pathway"],"prefix":"10.2174","volume":"27","author":[{"given":"Dongzhen","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingde","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minke","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwei","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Minhang Hospital, Fudan University, 170 Xin-Song Road, Shanghai, 201199, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"Ferlay J.","year":"2015","unstructured":"Ferlay J.; Soerjomataram I.; Dikshit R.; Eser S.; Mathers C.; Rebelo M.; Parkin D.M.; Forman D.; Bray F.; Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015,136(5),E359-E386","journal-title":"Int J Cancer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"12099","DOI":"10.18632\/aging.202917","volume":"13","author":"Qu G.","year":"2021","unstructured":"Qu G.; Liu Z.; Yang G.; Xu Y.; Xiang M.; Tang C.; Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer. Aging 2021,13(8),12099-12112","journal-title":"Aging"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"Lenis A.T.","year":"2020","unstructured":"Lenis A.T.; Lec P.M.; Chamie K.; Mshs M.; Bladder cancer. JAMA 2020,324(19),1980-1991","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","volume":"71","author":"Dy G.W.","year":"2017","unstructured":"Dy G.W.; Gore J.L.; Forouzanfar M.H.; Naghavi M.; Fitzmaurice C.; Global burden of urologic cancers, 1990\u20132013. Eur Urol 2017,71(3),437-446","journal-title":"Eur Urol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","volume":"27","author":"Sievert K.D.","year":"2009","unstructured":"Sievert K.D.; Amend B.; Nagele U.; Schilling D.; Bedke J.; Horstmann M.; Hennenlotter J.; Kruck S.; Stenzl A.; Economic aspects of bladder cancer: What are the benefits and costs? World J Urol 2009,27(3),295-300","journal-title":"World J Urol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"Humphrey P.A.","year":"2016","unstructured":"Humphrey P.A.; Moch H.; Cubilla A.L.; Ulbright T.M.; Reuter V.E.; The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part B: Prostate and bladder tumours. Eur Urol 2016,70(1),106-119","journal-title":"Eur Urol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","volume":"8","author":"Saginala K.","year":"2020","unstructured":"Saginala K.; Barsouk A.; Aluru J.S.; Rawla P.; Padala S.A.; Barsouk A.; Epidemiology of bladder cancer. Med Sci 2020,8(1),15","journal-title":"Med Sci"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/0970-1591.166445","volume":"31","author":"Konety B.","year":"2015","unstructured":"Konety B.; Isharwal S.; Non-muscle invasive bladder cancer risk stratification. Indian J Urol 2015,31(4),289-296","journal-title":"Indian J Urol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/BLC-160053","volume":"2","author":"Lerner S.P.","year":"2016","unstructured":"Lerner S.P.; Bajorin D.F.; Dinney C.P.; Efstathiou J.A.; Groshen S.; Hahn N.M.; Hansel D.; Kwiatkowski D.; O\u2019Donnell M.; Rosenberg J.; Svatek R.; Abrams J.S.; Al-Ahmadie H.; Apolo A.B.; Bellmunt J.; Callahan M.; Cha E.K.; Drake C.; Jarow J.; Kamat A.; Kim W.; Knowles M.; Mann B.; Marchionni L.; McConkey D.; McShane L.; Ramirez N.; Sharabi A.; Sharpe A.H.; Solit D.; Tangen C.M.; Amiri A.T.; Van Allen E.; West P.J.; Witjes J.A.; Quale D.Z.; Summary and recommendations from the National Cancer Institute\u2019s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. Bladder Cancer 2016,2(2),165-202","journal-title":"Bladder Cancer"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1002\/ctd2.176","volume":"3","author":"Wang G.","year":"2023","unstructured":"Wang G.; Jin W.; Xu Z.; Ju L.; Shan D.; Li S.; Yu M.; Cao X.; Liu N.; Qian K.; Zhang Y.; Xiao Y.; Wang X.; Urine\u2010based liquid biopsy in bladder cancer: Opportunities and challenges. Clin Transl Discov 2023,3(1),e176","journal-title":"Clin Transl Discov"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12885-022-09376-9","volume":"22","author":"Bhattacharjee S.","year":"2022","unstructured":"Bhattacharjee S.; Sullivan M.J.; Wynn R.R.; Demagall A.; Hendrix A.S.; Sindhwani P.; Petros F.G.; Nadiminty N.; PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. BMC Cancer 2022,22(1),312","journal-title":"BMC Cancer"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.urolonc.2013.06.001","volume":"32","author":"Xylinas E.","year":"2014","unstructured":"Xylinas E.; Urine markers for detection and surveillance of bladder cancer. Urol Oncol 2014,32(3),222-229","journal-title":"Urol Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"37500","DOI":"10.18632\/oncotarget.6061","volume":"6","author":"Cai Q.","year":"2015","unstructured":"Cai Q.; Wu Y.; Guo Z.; Gong R.; Tang Y.; Yang K.; Li X.; Guo X.; Niu Y.; Zhao Y.; Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: A pooled analysis of individual studies. Oncotarget 2015,6(35),37500-37510","journal-title":"Oncotarget"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/107327481001700406","volume":"17","author":"Sexton W.J.","year":"2010","unstructured":"Sexton W.J.; Wiegand L.R.; Correa J.J.; Politis C.; Dickinson S.I.; Kang L.C.; Bladder cancer: A review of non-muscle invasive disease. Cancer Contr 2010,17(4),256-268","journal-title":"Cancer Contr"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1517\/17425255.2015.1005600","volume":"11","author":"Narayan V.","year":"2015","unstructured":"Narayan V.; Vaughn D.; Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. Expert Opin Drug Metab Toxicol 2015,11(5),731-742","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"15822","DOI":"10.1038\/s41598-020-72820-y","volume":"10","author":"Reesink D.J.","year":"2020","unstructured":"Reesink D.J.; van de Garde E.M.W.; Peters B.J.M.; van der Nat P.B.; Los M.; Horenblas S.; van Melick H.H.E.; Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. Sci Rep 2020,10(1),15822","journal-title":"Sci Rep"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"17588359211045858","DOI":"10.1177\/17588359211045858","volume":"13","author":"Kaur J.","year":"2021","unstructured":"Kaur J.; Choi W.; Geynisman D.M.; Plimack E.R.; Ghatalia P.; Role of immunotherapy in localized muscle invasive urothelial cancer. Ther Adv Med Oncol 2021,13,17588359211045858","journal-title":"Ther Adv Med Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","volume":"59","author":"Stenzl A.","year":"2011","unstructured":"Stenzl A.; Cowan N.C.; De Santis M.; Kuczyk M.A.; Merseburger A.S.; Ribal M.J.; Sherif A.; Witjes J.A.; Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur Urol 2011,59(6),1009-1018","journal-title":"Eur Urol"},{"key":"ref=19","first-page":"485","volume":"7","author":"Yang Z.","year":"2021","unstructured":"Yang Z.; Xu Y.; Bi Y.; Zhang N.; Wang H.; Xing T.; Bai S.; Shen Z.; Naz F.; Zhang Z.; Yin L.; Shi M.; Wang L.; Wang L.; Wang S.; Xu L.; Su X.; Wu S.; Yu C.; Immune escape mechanisms and immunotherapy of urothelial bladder cancer. J Clin Transl Res 2021,7(4),485-500","journal-title":"J Clin Transl Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/cancers12051181","volume":"12","year":"2020","unstructured":"Wo\u0142\u0105cewicz, M.; Hrynkiewicz, R.; Grywalska, E.; Suchojad, T.; Leksowski, T.; Roli\u0144ski, J.; Nied\u017awiedzka-Rystwej, P. Immunotherapy in bladder cancer: Current methods and future perspectives. Cancers 2020,12(5),1181","journal-title":"Cancers"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"568279","DOI":"10.3389\/fonc.2020.568279","volume":"10","author":"Zucali P.A.","year":"2020","unstructured":"Zucali P.A.; Cordua N.; D\u2019Antonio F.; Borea F.; Perrino M.; De Vincenzo F.; Santoro A.; Current perspectives on immunotherapy in the peri-operative setting of muscle-infiltrating bladder cancer. Front Oncol 2020,10,568279","journal-title":"Front Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13046-022-02377-3","volume":"41","author":"Chi M.","year":"2022","unstructured":"Chi M.; Liu J.; Mei C.; Shi Y.; Liu N.; Jiang X.; Liu C.; Xue N.; Hong H.; Xie J.; Sun X.; Yin B.; Meng X.; Wang B.; TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K\/AKT pathway in bladder cancer. J Exp Clin Cancer Res 2022,41(1),175","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13073-019-0669-z","volume":"11","author":"de Jong J.J.","year":"2019","unstructured":"de Jong J.J.; Liu Y.; Robertson A.G.; Seiler R.; Groeneveld C.S.; van der Heijden M.S.; Wright J.L.; Douglas J.; Dall\u2019Era M.; Crabb S.J.; van Rhijn B.W.G.; van Kessel K.E.M.; Davicioni E.; Castro M.A.A.; Lotan Y.; Zwarthoff E.C.; Black P.C.; Boormans J.L.; Gibb E.A.; Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Med 2019,11(1),60","journal-title":"Genome Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"Robertson A.G.","year":"2017","unstructured":"Robertson A.G.; Kim J.; Al-Ahmadie H.; Bellmunt J.; Guo G.; Cherniack A.D.; Hinoue T.; Laird P.W.; Hoadley K.A.; Akbani R.; Castro M.A.A.; Gibb E.A.; Kanchi R.S.; Gordenin D.A.; Shukla S.A.; Sanchez-Vega F.; Hansel D.E.; Czerniak B.A.; Reuter V.E.; Su X.; de Sa Carvalho B.; Chagas V.S.; Mungall K.L.; Sadeghi S.; Pedamallu C.S.; Lu Y.; Klimczak L.J.; Zhang J.; Choo C.; Ojesina A.I.; Bullman S.; Leraas K.M.; Lichtenberg T.M.; Wu C.J.; Schultz N.; Getz G.; Meyerson M.; Mills G.B.; McConkey D.J.; Weinstein J.N.; Kwiatkowski D.J.; Lerner S.P.; Akbani R.; Al-Ahmadie H.; Albert M.; Alexopoulou I.; Ally A.; Antic T.; Aron M.; Balasundaram M.; Bartlett J.; Baylin S.B.; Beaver A.; Bellmunt J.; Birol I.; Boice L.; Bootwalla M.S.; Bowen J.; Bowlby R.; Brooks D.; Broom B.M.; Bshara W.; Bullman S.; Burks E.; C\u00e1rcano F.M.; Carlsen R.; Carvalho B.S.; Carvalho A.L.; Castle E.P.; Castro M.A.A.; Castro P.; Catto J.W.; Chagas V.S.; Cherniack A.D.; Chesla D.W.; Choo C.; Chuah E.; Chudamani S.; Cortessis V.K.; Cottingham S.L.; Crain D.; Curley E.; Czerniak B.A.; Daneshmand S.; Demchok J.A.; Dhalla N.; Djaladat H.; Eckman J.; Egea S.C.; Engel J.; Felau I.; Ferguson M.L.; Gardner J.; Gastier-Foster J.M.; Gerken M.; Getz G.; Gibb E.A.; Gomez-Fernandez C.R.; Gordenin D.A.; Guo G.; Hansel D.E.; Harr J.; Hartmann A.; Herbert L.M.; Hinoue T.; Ho T.H.; Hoadley K.A.; Holt R.A.; Hutter C.M.; Jones S.J.M.; Jorda M.; Kahnoski R.J.; Kanchi R.S.; Kasaian K.; Kim J.; Klimczak L.J.; Kwiatkowski D.J.; Lai P.H.; Laird P.W.; Lane B.R.; Leraas K.M.; Lerner S.P.; Lichtenberg T.M.; Liu J.; Lolla L.; Lotan Y.; Lu Y.; Lucchesi F.R.; Ma Y.; Machado R.D.; Maglinte D.T.; Mallery D.; Marra M.A.; Martin S.E.; Mayo M.; McConkey D.J.; Meraney A.; Meyerson M.; Mills G.B.; Moinzadeh A.; Moore R.A.; Mora Pinero E.M.; Morris S.; Morrison C.; Mungall K.L.; Mungall A.J.; Myers J.B.; Naresh R.; O\u2019Donnell P.H.; Ojesina A.I.; Parekh D.J.; Parfitt J.; Paulauskis J.D.; Sekhar Pedamallu C.; Penny R.J.; Pihl T.; Porten S.; Quintero-Aguilo M.E.; Ramirez N.C.; Rathmell W.K.; Reuter V.E.; Rieger-Christ K.; Robertson A.G.; Sadeghi S.; Saller C.; Salner A.; Sanchez-Vega F.; Sandusky G.; Scapulatempo-Neto C.; Schein J.E.; Schuckman A.K.; Schultz N.; Shelton C.; Shelton T.; Shukla S.A.; Simko J.; Singh P.; Sipahimalani P.; Smith N.D.; Sofia H.J.; Sorcini A.; Stanton M.L.; Steinberg G.D.; Stoehr R.; Su X.; Sullivan T.; Sun Q.; Tam A.; Tarnuzzer R.; Tarvin K.; Taubert H.; Thiessen N.; Thorne L.; Tse K.; Tucker K.; Van Den Berg D.J.; van Kessel K.E.; Wach S.; Wan Y.; Wang Z.; Weinstein J.N.; Weisenberger D.J.; Wise L.; Wong T.; Wu Y.; Wu C.J.; Yang L.; Zach L.A.; Zenklusen J.C.; Zhang J.J.; Zhang J.; Zmuda E.; Zwarthoff E.C.; Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2017,171(3),540-556.e25","journal-title":"Cell"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/0008-5472.CAN-20-2336","volume":"81","author":"Wullweber A.","year":"2021","unstructured":"Wullweber A.; Strick R.; Lange F.; Sikic D.; Taubert H.; Wach S.; Wullich B.; Bertz S.; Weyerer V.; Stoehr R.; Breyer J.; Burger M.; Hartmann A.; Strissel P.L.; Eckstein M.; Bladder tumor subtype commitment occurs in carcinoma in situ driven by key signaling pathways including ECM remodeling. Cancer Res 2021,81(6),1552-1566","journal-title":"Cancer Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"Tran L.","year":"2021","unstructured":"Tran L.; Xiao J.F.; Agarwal N.; Duex J.E.; Theodorescu D.; Advances in bladder cancer biology and therapy. Nat Rev Cancer 2021,21(2),104-121","journal-title":"Nat Rev Cancer"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"Alfred Witjes J.","year":"2017","unstructured":"Alfred Witjes J.; Lebret T.; Comp\u00e9rat E.M.; Cowan N.C.; De Santis M.; Bruins H.M.; Hern\u00e1ndez V.; Espin\u00f3s E.L.; Dunn J.; Rouanne M.; Neuzillet Y.; Veskim\u00e4e E.; van der Heijden A.G.; Gakis G.; Ribal M.J.; Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017,71(3),462-475","journal-title":"Eur Urol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1516.e9","DOI":"10.1016\/j.urology.2009.08.055","volume":"75","author":"Kim E-J.","year":"2010","unstructured":"Kim E-J.; Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology 2010,75(6),1516.e9-13","journal-title":"Urology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12935-019-0859-1","volume":"19","author":"Liu J.","year":"2019","unstructured":"Liu J.; Zhou S.; Li S.; Jiang Y.; Wan Y.; Ma X.; Cheng W.; Eleven genes associated with progression and prognosis of endometrial cancer (EC) identified by comprehensive bioinformatics analysis. Cancer Cell Int 2019,19(1),136","journal-title":"Cancer Cell Int"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ng1532","volume":"37","author":"Basso K.","year":"2005","unstructured":"Basso K.; Margolin A.A.; Stolovitzky G.; Klein U.; Dalla-Favera R.; Califano A.; Reverse engineering of regulatory networks in human B cells. Nat Genet 2005,37(4),382-390","journal-title":"Nat Genet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/s41598-017-02990-9","volume":"7","author":"Zeng S.","year":"2017","unstructured":"Zeng S.; Yu X.; Ma C.; Song R.; Zhang Z.; Zi X.; Chen X.; Wang Y.; Yu Y.; Zhao J.; Wei R.; Sun Y.; Xu C.; Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. Sci Rep 2017,7(1),3151","journal-title":"Sci Rep"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/1756287216638981","volume":"8","author":"Mitra A.P.","year":"2016","unstructured":"Mitra A.P.; Molecular substratification of bladder cancer: Moving towards individualized patient management. Ther Adv Urol 2016,8(3),215-233","journal-title":"Ther Adv Urol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1002\/jcb.26050","volume":"118","author":"Liu X.","year":"2017","unstructured":"Liu X.; Hu A.X.; Zhao J.L.; Chen F.L.; Identification of key gene modules in human osteosarcoma by co\u2010expression analysis weighted gene co\u2010expression network analysis (WGCNA). J Cell Biochem 2017,118(11),3953-3959","journal-title":"J Cell Biochem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1515\/sagmb-2021-0025","volume":"20","author":"Shuai M.","year":"2021","unstructured":"Shuai M.; He D.; Chen X.; Optimizing weighted gene co-expression network analysis with a multi-threaded calculation of the topological overlap matrix. Stat Appl Genet Mol Biol 2021,20(4-6),145-153","journal-title":"Stat Appl Genet Mol Biol"},{"key":"ref=35","first-page":"385","author":"Ko D.K.","year":"2022","unstructured":"Ko D.K.; Brandizzi F.; Coexpression network construction and visualization from transcriptomes underlying ER stress responses. Plant Proteostasis: Methods and Protocols 2022,385-401","journal-title":"Plant Proteostasis: Methods and Protocols"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.gene.2019.05.010","volume":"710","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; Liu T.; Liu Y.; Chen J.; Xin B.; Wu M.; Cui W.; Coronary artery disease associated specific modules and feature genes revealed by integrative methods of WGCNA, MetaDE and machine learning. Gene 2019,710,122-130","journal-title":"Gene"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1533033820957011","DOI":"10.1177\/1533033820957011","volume":"19","author":"Wu J.","year":"2020","unstructured":"Wu J.; Liu X.J.; Hu J.N.; Liao X.H.; Lin F.F.; Transcriptomics and prognosis analysis to identify critical biomarkers in invasive breast carcinoma. Technol Cancer Res Treat 2020,19,1533033820957011","journal-title":"Technol Cancer Res Treat"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.3390\/cancers13133148","volume":"13","author":"Park Y.","year":"2021","unstructured":"Park Y.; Heider D.; Hauschild A.C.; Integrative analysis of next-generation sequencing for next-generation cancer research toward artificial intelligence. Cancers 2021,13(13),3148","journal-title":"Cancers"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1007\/s10620-017-4718-4","volume":"62","author":"Zhou Z.","year":"2017","unstructured":"Zhou Z.; Liu S.; Zhang M.; Zhou R.; Liu J.; Chang Y.; Zhao Q.; Overexpression of topoisomerase 2-alpha confers a poor prognosis in pancreatic adenocarcinoma identified by co-expression analysis. Dig Dis Sci 2017,62(10),2790-2800","journal-title":"Dig Dis Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","volume":"173","author":"Blum A.","year":"2018","unstructured":"Blum A.; Wang P.; Zenklusen J.C.; SnapShot: TCGA-analyzed tumors. Cell 2018,173(2),530","journal-title":"Cell"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nrg2345","volume":"9","author":"Loeb L.A.","year":"2008","unstructured":"Loeb L.A.; Monnat R.J.; DNA polymerases and human disease. Nat Rev Genet 2008,9(8),594-604","journal-title":"Nat Rev Genet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/path.4185","volume":"230","author":"Briggs S.","year":"2013","unstructured":"Briggs S.; Tomlinson I.; Germline and somatic polymerase \u03f5 and \u03b4 mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 2013,230(2),148-153","journal-title":"J Pathol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41419-021-04498-7","volume":"13","author":"Zhang P.","year":"2022","unstructured":"Zhang P.; Chen X.; Zhang L.; Cao D.; Chen Y.; Guo Z.; Chen J.; POLE2 facilitates the malignant phenotypes of glioblastoma through promoting AURKA-mediated stabilization of FOXM1. Cell Death Dis 2022,13(1),61","journal-title":"Cell Death Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12935-020-01477-4","volume":"20","author":"Zhu Y.","year":"2020","unstructured":"Zhu Y.; Chen G.; Song Y.; Chen Z.; Chen X.; POLE2 knockdown reduce tumorigenesis in esophageal squamous cells. Cancer Cell Int 2020,20(1),388","journal-title":"Cancer Cell Int"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3892\/ijo.2014.2510","volume":"45","author":"Liu D.","year":"2014","unstructured":"Liu D.; Zhang X.X.; Xi B.X.; Wan D.Y.; Li L.; Zhou J.; Wang W.; Ma D.; Wang H.; Gao Q.L.; Sine oculis homeobox homolog 1 promotes DNA replication and cell proliferation in cervical cancer. Int J Oncol 2014,45(3),1232-1240","journal-title":"Int J Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3892\/or.2018.6659","volume":"40","author":"Li J.","year":"2018","unstructured":"Li J.; Wang J.; Yu J.; Zhao Y.; Dong Y.; Fan Y.; Li N.; Zhang Y.; Wang Y.; Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro. Oncol Rep 2018,40(5),2477-2486","journal-title":"Oncol Rep"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e0211737","DOI":"10.1371\/journal.pone.0211737","volume":"14","author":"Pearlman A.","year":"2019","unstructured":"Pearlman A.; Rahman M.T.; Upadhyay K.; Loke J.; Ostrer H.; Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions. PLoS One 2019,14(2),e0211737","journal-title":"PLoS One"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11010-023-04738-8","volume":"479","author":"Lv Z.","year":"2023","unstructured":"Lv Z.; Wu X.; Lu P.; Xu X.; Wang J.; Zhang C.; Liu W.; Gao Y.; Lu C.; Zhang Y.; Kou H.; POLE2 knockdown suppresses lymphoma progression via downregulating Wnt\/\u03b2-catenin signaling pathway. Mol Cell Biochem 2023,479,487-497","journal-title":"Mol Cell Biochem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/82_2017_6","volume":"407","author":"Aoki M.","year":"2017","unstructured":"Aoki M.; Fujishita T.; Oncogenic roles of the PI3K\/AKT\/mTOR axis. Curr Top Microbiol Immunol 2017,407,153-189","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cells9040806","volume":"9","author":"Su Y.L.","year":"2020","unstructured":"Su Y.L.; Luo H.L.; Huang C.C.; Liu T.T.; Huang E.Y.; Sung M.T.; Lin J.J.; Chiang P.H.; Chen Y.T.; Kang C.H.; Cheng Y.T.; Galectin-1 overexpression activates the FAK\/PI3K\/AKT\/mTOR pathway and is correlated with upper urinary urothelial carcinoma progression and survival. Cells 2020,9(4),806","journal-title":"Cells"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"9915","DOI":"10.18632\/aging.103256","volume":"12","author":"Yao J.","year":"2020","unstructured":"Yao J.; Qian K.; Chen C.; Liu X.; Yu D.; Yan X.; Liu T.; Li S.; ZNF139\/circZNF139 promotes cell proliferation, migration and invasion via activation of PI3K\/AKT pathway in bladder cancer. Aging 2020,12(10),9915-9934","journal-title":"Aging"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ncpuro0510","volume":"3","author":"Pelucchi C.","year":"2006","unstructured":"Pelucchi C.; Bosetti C.; Negri E.; Malvezzi M.; La Vecchia C.; Mechanisms of Disease: The epidemiology of bladder cancer. Nat Clin Pract Urol 2006,3(6),327-340","journal-title":"Nat Clin Pract Urol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/biology10060533","volume":"10","author":"Hatta M.N.A.","year":"2021","unstructured":"Hatta M.N.A.; Mohamad Hanif E.A.; Chin S.F.; Neoh H.; Pathogens and carcinogenesis: A review. Biology 2021,10(6),533","journal-title":"Biology"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"Siegel R.L.","year":"2022","unstructured":"Siegel R.L.; Miller K.D.; Fuchs H.E.; Jemal A.; Cancer statistics, 2022. CA Cancer J Clin 2022,72(1),7-33","journal-title":"CA Cancer J Clin"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"Xia C.","year":"2022","unstructured":"Xia C.; Dong X.; Li H.; Cao M.; Sun D.; He S.; Yang F.; Yan X.; Zhang S.; Li N.; Chen W.; Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J 2022,135(5),584-590","journal-title":"Chin Med J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"von der Maase H.","year":"2000","unstructured":"von der Maase H.; Hansen S.W.; Roberts J.T.; Dogliotti L.; Oliver T.; Moore M.J.; Bodrogi I.; Albers P.; Knuth A.; Lippert C.M.; Kerbrat P.; Sanchez Rovira P.; Wersall P.; Cleall S.P.; Roychowdhury D.F.; Tomlin I.; Visseren-Grul C.M.; Conte P.F.; Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000,18(17),3068-3077","journal-title":"J Clin Oncol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","volume":"5","author":"Aggen D.H.","year":"2017","unstructured":"Aggen D.H.; Drake C.G.; Biomarkers for immunotherapy in bladder cancer: A moving target. J Immunother Cancer 2017,5(1),94","journal-title":"J Immunother Cancer"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","volume":"18","author":"Flaig T.W.","year":"2020","unstructured":"Flaig T.W.; Spiess P.E.; Agarwal N.; Bangs R.; Boorjian S.A.; Buyyounouski M.K.; Chang S.; Downs T.M.; Efstathiou J.A.; Friedlander T.; Greenberg R.E.; Guru K.A.; Guzzo T.; Herr H.W.; Hoffman-Censits J.; Hoimes C.; Inman B.A.; Jimbo M.; Kader A.K.; Lele S.M.; Michalski J.; Montgomery J.S.; Nandagopal L.; Pagliaro L.C.; Pal S.K.; Patterson A.; Plimack E.R.; Pohar K.S.; Preston M.A.; Sexton W.J.; Siefker-Radtke A.O.; Tward J.; Wright J.L.; Gurski L.A.; Johnson-Chilla A.; Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020,18(3),329-354","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"9854","DOI":"10.3390\/ijms24129854","volume":"24","author":"Gilyazova I.","year":"2023","unstructured":"Gilyazova I.; Enikeeva K.; Rafikova G.; Kagirova E.; Sharifyanova Y.; Asadullina D.; Pavlov V.; Epigenetic and immunological features of bladder cancer. Int J Mol Sci 2023,24(12),9854","journal-title":"Int J Mol Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/14656566.3.6.755","volume":"3","author":"Markman M.","year":"2002","unstructured":"Markman M.; Mekhail T.M.; Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002,3(6),755-766","journal-title":"Expert Opin Pharmacother"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41419-021-04260-z","volume":"12","author":"Yi L.","year":"2021","unstructured":"Yi L.; Wang H.; Li W.; Ye K.; Xiong W.; Yu H.; Jin X.; The FOXM1\/RNF26\/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer. Cell Death Dis 2021,12(10),944","journal-title":"Cell Death Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/cancers12061417","volume":"12","author":"Roh Y.G.","year":"2020","unstructured":"Roh Y.G.; Mun J.Y.; Kim S.K.; Park W.Y.; Jeong M.S.; Kim T.N.; Kim W.T.; Choi Y.H.; Chu I.S.; Leem S.H.; Fanconi anemia pathway activation by FOXM1 is critical to bladder cancer recurrence and anticancer drug resistance. Cancers 2020,12(6),1417","journal-title":"Cancers"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"7681","DOI":"10.1038\/sj.onc.1202954","volume":"18","author":"Yap D.B.S.","year":"1999","unstructured":"Yap D.B.S.; Hsieh J.K.; Chan F.S.G.; Lu X.; mdm2: A bridge over the two tumour suppressors, p53 and Rb. Oncogene 1999,18(53),7681-7689","journal-title":"Oncogene"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2006.0033","DOI":"10.1038\/msb4100068","volume":"2","year":"2006","unstructured":"Oscillations and variability in the p53 system. Mol Syst Biol Geva\u2010Zatorsky, N 2006,2,2006.0033","journal-title":"Mol Syst Biol"},{"key":"ref=66","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-023-00823-8","author":"Shi T.","year":"2023","unstructured":"Shi T.; Yuan Z.; He Y.; Zhang D.; Chen S.; Wang X.; Yao L.; Shao J.; Wang X.; Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer. Cell Oncol 2023","journal-title":"Cell Oncol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/2211-5463.13262","volume":"11","author":"Yang Z.","year":"2021","unstructured":"Yang Z.; Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activation of the p38\/p53\/p21 signalling pathway in bladder cancer. FEBS Open Bio 2021,11(9),2631-2646","journal-title":"FEBS Open Bio"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1871520623666221026121600","volume":"23","author":"Long X.","year":"2023","unstructured":"Long X.; Network-based pharmacology and in vitro validation reveal that galangin induces apoptosis in bladder cancer cells by promoting the p53 signaling pathway. Anticancer Agents Med Chem 2023,23(7),847-857","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=69","first-page":"195","volume":"17","author":"Ye G.","year":"2019","unstructured":"Ye G.; Kan S.; Chen J.; Lu X.; Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1\/p53 pathway. Oncol Lett 2019,17(1),195-200","journal-title":"Oncol Lett"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000524204","volume":"107","author":"Chen S.","year":"2023","unstructured":"Chen S.; ANLN serves as an oncogene in bladder urothelial carcinoma via activating JNK signaling pathway. Urol Int 2023,107(3),310-320","journal-title":"Urol Int"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.3390\/cancers11121840","volume":"11","author":"Wu S.","year":"2019","unstructured":"Wu S.; Nitschke K.; Heinkele J.; Weis C.A.; Worst T.S.; Eckstein M.; Porubsky S.; Erben P.; ANLN and TLE2 in muscle invasive bladder cancer: A functional and clinical evaluation based on in silico and in vitro data. Cancers 2019,11(12),1840","journal-title":"Cancers"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"e921430","DOI":"10.12659\/MSM.921430","volume":"26","author":"Wu Z.","year":"2020","unstructured":"Wu Z.; Wang Y.M.; Dai Y.; Chen L.A.; POLE2 serves as a prognostic biomarker and is associated with immune infiltration in squamous cell lung cancer. Med Sci Monit 2020,26,e921430-e921431","journal-title":"Med Sci Monit"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","volume":"41","author":"Ma X.","year":"2022","unstructured":"Ma X.; Dong L.; Liu X.; Ou K.; Yang L.; POLE\/POLD1 mutation and tumor immunotherapy. J Exp Clin Cancer Res 2022,41(1),216","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=74","first-page":"329","volume":"24","author":"Kachrilas S.","year":"2019","unstructured":"Kachrilas S.; Dellis A.; Papatsoris A.; Avgeris S.; Anastasiou D.; Gavriil A.; Horti M.; Tseleni Balafouta S.; Livadas K.; Stravopodis D.J.; Alivizatos G.; Voutsinas G.E.; Deliveliotis C.; PI3K\/AKT pathway genetic alterations and dysregulation of expression in bladder cancer. J BUON 2019,24(1),329-337","journal-title":"J BUON"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00432-008-0478-z","volume":"135","author":"Qian Y.","year":"2009","unstructured":"Qian Y.; Deng J.; Xie H.; Geng L.; Zhou L.; Wang Y.; Yin S.; Feng X.; Zheng S.; Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. J Cancer Res Clin Oncol 2009,135(3),379-386","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113862073273633231113060429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223844\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113862073273633231113060429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T11:28:26Z","timestamp":1730719706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223844\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":75,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113862073273633231113060429","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}